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did not provide details of the sample selection. No patients appear to have refused to participate in the study, nor did any appear to have been excluded from the study. There were 504 patients randomised to receive PTCA and 514 randomised to receive medical therapy.
Study design
This was a randomised controlled trial. The study was multi-centred, involving 20 centres. The methods of randomisation were not reported in this study. Follow-up was for 3 years, with data being collected after 3 months, 6 months and then annually.
For patients in the PTCA group, there was 100% data completeness for the randomised treatment, 99% for subsequent events, 98% for days in hospital, 98% for outpatient and general practitioner (GP) visits and 98% for anti-anginal medication.
For patients in the medical therapy group, there was 100% data completeness for the randomised treatment, 99% for subsequent events, 97% for days in hospital, 97% for outpatient and GP visits, and 99% for anti-anginal medication.
Analysis of effectiveness
The primary health outcomes used were the number of deaths and the number of myocardial infarctions. Other outcomes recorded were the number of subsequent procedures and the number of days on anti-anginal medication. It was unclear whether the basis of the analysis was intention to treat or treatment completers only. It would appear that the groups were comparable at analysis.
Effectiveness results
After 3 years there had been 14 deaths in the PTCA group and 9 in the medical therapy group, and 7.3% of patients in the PTCA group reached the end point (defined as death or myocardial infarction) versus 4.1% in the medical therapy group, (p=0.025).
After 1 year, 17% of patients in the PTCA group had Grade 2 angina or worse, compared with 27.4% in the medical group (difference of 10.4%; p<0.001). By year 3, 19.5% of patients in the PTCA group had Grade 2 angina or worse, compared with 21.5% in the medical group, (difference of 2.0%).
Of the patients randomised to PTCA, 93% received PTCA.
Of the patients initially randomised to medical therapy, 18.1% underwent a subsequent coronary arteriogram, 19.8% underwent a subsequent PTCA, and 7.2% underwent a subsequent coronary artery bypass graft (CABG).
Of the patients initially randomised to PTCA, 25.9% underwent a subsequent coronary arteriogram, 12.3% underwent a subsequent PTCA, and 7.4% underwent a subsequent CABG.
There was higher use of anti-anginal medication (beta-blockers, long-acting nitrates and calcium antagonists) in patients initially randomised to medical therapy. On average, a higher number of inpatient days was used in the PTCA group. Outpatient visits were similar in the two groups.
Clinical conclusions
In patients with coronary artery disease considered suitable for either PTCA or medical care, early intervention with PTCA was associated with greater symptomatic improvement, especially in patients with more severe angina. There was a small excess hazard associated with PTCA, owing to procedure-related complications.
Measure of benefits used in the economic analysis
The authors did not derive a summary measure of health benefit. In effect, a cost-consequences analysis was performed.
